BioTrack Capital
BioTrack Capital is a Shanghai-based venture capital firm founded in 2017 that manages five funds with over USD 1.5 billion AUM, investing in and incubating early-stage biotech, medtech, AI/digital healthcare, and consumer healthcare companies, with more than 100 portfolio companies to date.
- Company typePrivate
- Founded2016
- HeadquartersShanghai, China
- Headcount1–10
- GTM typeB2B
- OfferingServices
What BioTrack Capital does
BioTrack operates an entrepreneur-founded investment model with a professional team whose complementary skills span research and development, clinical operations, consulting, and investment, led by Founding Partner & CEO Kevin Chen, Founding Partner Feng Tao, and Partner Lisa Lei. Revenue is generated through conventional VC mechanics: management fees on committed/invested capital across its five funds, supplemented by carried interest on realized exits. Distribution is direct, via the team's professional network and an ecosystem of leading global biopharma, medtech, and multinational healthcare conglomerates that the firm leverages both for deal sourcing and to support portfolio companies in going overseas. The firm is recognized by top-tier global LPs including pension funds, endowments, foundations, FOFs, family offices, and strategic partners, and it communicates with the market via its website and a monthly Viewpoint newsletter. As a private firm with 1-10 reported employees, BioTrack operates with a lean internal cost structure relative to its AUM scale.
BioTrack Capital firmographics
Firmographics- Name
- BioTrack Capital
- Legal name
- BioTrack Capital
- Website
- http://www.biotrackcapital.com/
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BioTrack Capital is a Shanghai-based venture capital firm founded in 2017 that manages five funds with over USD 1.5 billion AUM, investing in and incubating early-stage biotech, medtech, AI/digital healthcare, and consumer healthcare companies, with more than 100 portfolio companies to date.
- Ownership category
- akta.pro rank
BioTrack Capital industry classification
Industry- Product category
- Venture Capital Management
- NAICS
- Portfolio Management and Investment Advice (523940), Finance and Insurance (52)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where BioTrack Capital is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
BioTrack Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Distribution channels1 record
Marketing channels2 records
BioTrack Capital product offering
Product offeringCore offering
BioTrack Capital is a venture capital firm that invests in and incubates outstanding early-stage biotech, medtech, and healthcare cross-disciplinary companies (including AI and digital healthcare, and consumer healthcare). The firm manages five funds with total assets under management exceeding USD 1.5 billion and operates as both an investor and a long-term partner for entrepreneurs, providing capital, industry expertise, clinical operations support, consulting, and global expansion assistance to portfolio companies.
Product overview
BioTrack Capital is a venture capital firm established in 2017 that focuses on investing in and incubating outstanding early-stage biotech, medtech, and healthcare cross-disciplinary sectors including AI and digital healthcare, and consumer healthcare. The firm manages multiple investment funds (including Fund II with approximately USD 250 million) and offers venture capital investment services as its core offering. BioTrack positions itself as both an investor and long-term partner for entrepreneurs, with a portfolio of over 100 companies including public companies and sub-sector leaders. The firm operates an ecosystem consisting of leading global biopharma, medtech companies and multinational healthcare conglomerates to provide industry insights, value-add services, and global expansion support for portfolio companies.
Differentiator
Problem solved
Functional benefit
Products and services
- BioTrack Fund II
- Venture Capital Investment Services
Companies that use BioTrack Capital
Customer profileSegments2 records
Ideal customer profiles2 records
BioTrack Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BioTrack Capital partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
BioTrack Capital competitors and assessment
Company assessmentDirect peers
- Qiming Venture Partners: China-based venture capital firm with a dedicated healthcare/biotech practice investing across therapeutics, medtech, and digital health stages. Direct peer — BioTrack co-invested with Qiming in Syneron Bio's $150M Series B, and both firms serve the same Chinese biotech entrepreneur base.
- Hillhouse Capital (HHLR): Asia-focused investment firm with a sizeable healthcare and biotech practice covering early-stage therapeutics, medtech, and healthcare services. Comparable as a Chinese healthcare investor competing for similar biotech deal flow and overlapping LP base.
- Decheng Capital: Healthcare-focused venture capital firm investing in early- and growth-stage biotech, medtech, and digital health companies in China and the US. Direct peer — co-led Syneron Bio's $150M Series B alongside BioTrack, addressing the same founder pool.
- Yonjin Capital: Healthcare/biotech-focused venture capital firm based in China investing in innovative therapeutics and medtech. Direct peer — co-invested with BioTrack in Rapafusyn Pharmaceuticals' $44M Series A.
- Highlight Capital (弘晖资本): Chinese healthcare-specialist private equity firm investing across pharmaceuticals, biotech, medtech, and healthcare services. Comparable thesis, geography, and stage focus to BioTrack Capital.
- Loyal Valley Capital (君联资本/Orchid Asia-related funds vary; using Loyal Valley proper): China-focused alternative asset manager with dedicated healthcare and biotech investment programs. Comparable as a Chinese healthcare investor competing for similar founder relationships and capital pools.
- Apricot Capital: Asia-based healthcare/biotech-focused venture and growth investor focused on therapeutics and medical innovations. Comparable in sector specialization and Chinese biotech deal sourcing.
- Lake Bleu Capital: China-focused healthcare/biotech investment firm with both public and private equity strategies covering therapeutics, medtech, and healthcare services. Comparable to BioTrack in geography and healthcare specialization.
Broad incumbents
- CDH Investments (CDH VGC): Major China-based alternative asset manager with venture, growth, and buyout exposures including a dedicated healthcare practice. Comparable as a co-investor (Syneron Bio Series B) and as a broader incumbent whose healthcare team targets the same sectors at multiple stages.
Regional players
- Delian Capital (德联资本): China-focused venture capital firm with healthcare/biotech among its core investment themes. Comparable Chinese-anchored healthcare specialist addressing overlapping founder and LP ecosystems.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights5 records
Customer concentration
BioTrack Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioTrack Capital leadership team
Management profileNumber of profiles
Profiles5 records
BioTrack Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioTrack Capital M&A and investment
M&A and investmentM&A
Investments88 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioTrack Capital
What does BioTrack Capital do?
BioTrack Capital is a venture capital firm that invests in and incubates outstanding early-stage biotech, medtech, and healthcare cross-disciplinary companies (including AI and digital healthcare, and consumer healthcare). The firm manages five funds with total assets under management exceeding USD 1.5 billion and operates as both an investor and a long-term partner for entrepreneurs, providing capital, industry expertise, clinical operations support, consulting, and global expansion assistance to portfolio companies.
Is BioTrack Capital a public or private company?
BioTrack Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioTrack Capital founded?
BioTrack Capital was founded in 2016. It employs 1 to 10 people.
Where is BioTrack Capital based?
BioTrack Capital is headquartered in Shanghai, China, in the Asia region.
Who are BioTrack Capital's main competitors?
Direct peers on record are Qiming Venture Partners, Hillhouse Capital (HHLR), Decheng Capital, Yonjin Capital, Highlight Capital (弘晖资本), Loyal Valley Capital (君联资本/Orchid Asia-related funds vary; using Loyal Valley proper), Apricot Capital and Lake Bleu Capital. CDH Investments (CDH VGC) is listed as a broad incumbent. Delian Capital (德联资本) is listed as a regional player.
Does BioTrack Capital have an API?
No public API is recorded for BioTrack Capital.
What industry is BioTrack Capital in?
BioTrack Capital's product category is Venture Capital Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.